Acadia Pharmaceuticals to present trofinetide findings in Rett syndrome at AAN

The company states: “Acadia Pharmaceuticals announced that two oral presentations featuring DAYBUE findings in Rett syndrome will be presented at the American Academy of Neurology 2024 annual meeting, being held this week in Denver, CO. The presentations include outcomes from the DAFFODIL(TM), a Phase 2/3 open-label study evaluating the safety, tolerability and exploratory efficacy of DAYBUE in girls aged two to four living with Rett syndrome, as well as findings from exit interviews with caregivers of individuals living with Rett syndrome who participated in the LAVENDER(TM), LILAC(TM), LILAC-2(TM) and DAFFODIL studies.”